407 related articles for article (PubMed ID: 17438057)
1. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.
Arias CA; Singh KV; Panesso D; Murray BE
Antimicrob Agents Chemother; 2007 Jun; 51(6):2043-7. PubMed ID: 17438057
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model.
Arias CA; Singh KV; Panesso D; Murray BE
J Antimicrob Chemother; 2007 Sep; 60(3):594-8. PubMed ID: 17606481
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of high level aminoglycoside and vancomycin resistance among enterococci in Turkey.
Cirak MY; Sultan N
Acta Microbiol Pol; 1998; 47(3):267-73. PubMed ID: 9990710
[TBL] [Abstract][Full Text] [Related]
4. [Enterococci as uropathogens. Frequency of isolation and sensitivity to antibacterial agents].
Guirguitzova B; Chankova D; Zozikov B; Minkov N
Ann Urol (Paris); 1998; 32(1):15-9. PubMed ID: 9559070
[TBL] [Abstract][Full Text] [Related]
5. Synergistic activity of vancomycin and teicoplanin alone and in combination with streptomycin against Enterococcus faecalis strains with various vancomycin susceptibilities.
Babalola CP; Patel KB; Nightingale CH; Nicolau DP
Int J Antimicrob Agents; 2004 Apr; 23(4):343-8. PubMed ID: 15081082
[TBL] [Abstract][Full Text] [Related]
6. In vitro synergy of baicalein and gentamicin against vancomycin-resistant Enterococcus.
Chang PC; Li HY; Tang HJ; Liu JW; Wang JJ; Chuang YC
J Microbiol Immunol Infect; 2007 Feb; 40(1):56-61. PubMed ID: 17332908
[TBL] [Abstract][Full Text] [Related]
7. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
8. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Cha R
Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of Enterococcus faecalis to twelve antibiotics, time-kill assays, and high-level aminoglycoside resistance in a university hospital in Argentina.
Predari SC; Gutiérrez MA; Ribas C; Molinari GS; Santoianni JE
Rev Argent Microbiol; 1991; 23(2):67-78. PubMed ID: 1815269
[TBL] [Abstract][Full Text] [Related]
11. Time-kill study and synergistic activity of cell-wall inhibitor antibiotics in combination with gentamicin against Enterococcus faecalis and Enterococcus faecium.
Aligholi M; Emaneini M; Taherikalani M; Shahsavan S; Jabalameli F; Asadollahi P; Khoramian B; Eslampour MA
Acta Microbiol Immunol Hung; 2011 Sep; 58(3):219-26. PubMed ID: 21983323
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial resistance of enterococci in Turkey.
Kaçmaz B; Aksoy A
Int J Antimicrob Agents; 2005 Jun; 25(6):535-8. PubMed ID: 15908184
[TBL] [Abstract][Full Text] [Related]
13. Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE.
Werth BJ; Barber KE; Tran N; Nonejuie P; Sakoulas G; Pogliano J; Rybak MJ
J Antimicrob Chemother; 2015 Feb; 70(2):489-93. PubMed ID: 25304643
[TBL] [Abstract][Full Text] [Related]
14. [The relationship between antibiotic resistance and virulence factors in urinary Enterococcus isolates].
Baylan O; Nazik H; Bektöre B; Citil BE; Turan D; Ongen B; Ozyurt M; Açıkel CH; Haznedaroğlu T
Mikrobiyol Bul; 2011 Jul; 45(3):430-45. PubMed ID: 21935776
[TBL] [Abstract][Full Text] [Related]
15. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.
Kresken M; Körber-Irrgang B; Läuffer J; Decker-Burgard S; Davies T
Int J Antimicrob Agents; 2011 Jul; 38(1):70-5. PubMed ID: 21514795
[TBL] [Abstract][Full Text] [Related]
17. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study.
Rossolini GM; Dryden MS; Kozlov RS; Quintana A; Flamm RK; Läuffer JM; Lee E; Morrissey I; CLASS Study Group
J Antimicrob Chemother; 2011 Jan; 66(1):151-9. PubMed ID: 21051375
[TBL] [Abstract][Full Text] [Related]
18. In vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant Enterococcus isolates.
Tang HJ; Chen CC; Zhang CC; Su BA; Li CM; Weng TC; Chiang SR; Ko WC; Chuang YC
Diagn Microbiol Infect Dis; 2013 Nov; 77(3):254-7. PubMed ID: 24029433
[TBL] [Abstract][Full Text] [Related]
19. Synergy study of vancomycin or teicoplanin plus gentamicin against enterococci, Staphylococcus aureus and coagulase-negative staphylococci by time-kill method.
Thamlikitkul V
J Med Assoc Thai; 1991 Dec; 74(12):669-74. PubMed ID: 1839906
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
